Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus IODOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus IODOTOPE.
CERETEC vs IODOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical